Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Waldenstrom Macroglobulinemia 1Paraproteinemias 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Specimen Handling 9Practice Guidelines as Topic 7Standard of Care 6Taxes 4Paclitaxel 4Early Intervention, Educational 4Docetaxel 4pertuzumab 3pembrolizumab 3Trastuzumab 3Methods 3Educational Status 3Biopsy 3trastuzumab biosimilar HLX02 2PF-05280014 2Ontruzant 2Ogivri 2Minoxidil 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2High-Energy Shock Waves 2Cyclophosphamide 2Carboplatin 22C4 antibody 2regadenoson 1nilotinib 1fisetin 1abemaciclib 1Yoga 1X-Ray Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage I Breast Cancer AJCC v8 × Rifaximin × 1 year × Clear all
NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Mayo Clinic

Phase 2 Terminated
20 enrolled 13 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡